不同临床分期肝癌患者抗AFPTh1和Tc1应答反应研究

Immune Response of Hepatocellular Carcinoma of in Patients with Different Stages of Liver Function

目的:研究CD4(Th1)和CD8(Tc1)T细胞对肝癌患者的AFP的应答反应及其与临床特征的相关性,为其早期诊断与预防提供新策略。方法:研究对象为62例HCC患者,30例肝硬化患者及30例健康志愿者;重点分析CD4 T细胞和CD8 T细胞对HCC患者的AFP-衍生肽的反应;用胞内细胞因子检测法对IFN-γ进行检测。结果:抗AFP的Tc1反应检测阳性结果在对照组为28.5%,在OkudaⅠ期的肝癌患者中为25.0%,在Ⅱ或Ⅲ期的HCC患者中为31.6%。抗AFP Th1阳性反应仅在HCC患者中检测到。抗AFP Th1阳性反应在44.4%的Child-Pugh A级的HCC患者中检测到,但是在Child-Pugh B或C级中仅15.4%。Tc1型反应在Child-Pugh A级肝功的患者中为16.7%,在Child-Pugh B或C级患者中为46.2%。结论:抗AFP Th1应答更多出现在早期肝硬化的HCC的患者中,而抗AFP Tc1应答更可能出现在晚期肝硬化患者中,这些结论为抗肝癌疫苗药物设计提供了理论基础。

Objective： Alpha-Fetoprotein（AFP） is a kind of tumor associated antigen in hepatocellular carcinoma（HCC）, and it is also the target of immune therapy. However, there is little information on the pattern of CD4（Th1） and CD8（Tc1） T-cell response to AFP in patients with HCC or on their association with clinical characteristic of patients. Therefore, we observed the CD4（Th1） and CD8（Tc1） response of T cells in patients with hepatocellular carcinoma AFP and its clinical features. Methods： The subjects were 62 Patients with HCC, 30 patients with liver cirrhosis and 30 healthy people as control. CD4 and CD8T-cell responses to AFP-derived peptides of 62 HCC patients were studied, and intracellular cytokine method was applied to detect IFN- γ. Results： The rate of positive results of Tc1 reaction of anti AFP was 28.5% in the control group, 25.0% in patients with hepatocellular carcinoma in Okuda Ⅰ, and in phaseⅡ or III of HCC patients was 31.6%. Anti AFP Th1 positive reaction was detected only in HCC patients. 44.4% of HCC patients with Child-Pugh A were Th1 reaction; however, this was detected in only 15.4% with B or C score. Tc1 reaction was detected in 16.7% of patients with Child-Pugh A and Child-Pugh B or C level was 46.2%. Conclusion： The results show that anti-AFP Th1 reactions mainly occurred in patients with disease in early stage, anti AFP Tc1 responses are more likely to occur in patients with late stage cirrhosis, therefore, these data provide effective information for vaccine design against hepatocellular carcinoma.